Emboline, Inc. Closes $20 Million Funding to Enhance Embolic Protection System Innovation

Emboline, Inc. Secures Vital Funding for Groundbreaking Technology

Emboline, Inc., a burgeoning name in medical technology, has successfully acquired $20 million in growth financing from Trinity Capital, a prominent alternative asset manager. This investment is geared towards accelerating the commercialization of Embolline's innovative Emboliner® Embolic Protection System, designed to mitigate stroke risks associated with transcatheter aortic valve replacement (TAVR) surgeries.

The announcement made earlier this year highlights Emboline's commitment to reducing the incidences of stroke and ischemic damage that can occur during these structural heart procedures. The funding comes at a crucial time, as Emboline recently finalized patient enrollment in its PROTECT H2H investigational device exemption (IDE) clinical trial (NCT05684146). This rigorous study evaluates the efficacy of the Emboliner® system in protecting patients during complex heart interventions.

The Emboliner® Embolic Protection System functions by capturing debris—embolic materials released during transcatheter heart procedures—thereby preventing these particles from traveling to vital organs, including the brain. This innovative approach not only aims to protect patient health during surgeries but also represents a significant advancement in the field of cardiac care.

Furthermore, Emboline boasts an extensive intellectual property portfolio related to aortic embolic protection technologies. This includes novel approaches to full-body embolic filtration and innovative methods for aortic deflection, broadening the company's scope in the medical device market.

Scott Russell, the President and CEO of Emboline, expressed enthusiasm regarding the partnership with Trinity Capital, stating, "We are thrilled to have the support of Trinity Capital during this critical period as we prepare for our commercial launch in both the United States and Europe. With the completion of the IDE clinical trial and our upcoming regulatory submissions, we are poised to offer a comprehensive embolic protection solution to physicians worldwide."

Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, also commented on the significance of this financing, stating that the Emboliner's innovative technology is set to provide interventional cardiologists with the assurance needed to perform complex heart procedures while minimizing the risk of stroke and other embolic complications.

The results from the completed IDE clinical study will be a focal point at the American College of Cardiology's Annual Scientific Session set for March 29, 2026, in New Orleans, Louisiana. This large-scale clinical trial is expected to yield pivotal insights that can further propel the Emboliner® system into the commercial spotlight.

With the closing of this funding round, Emboline is directed towards launching the Emboliner® Embolic Protection System commercially while simultaneously pursuing the development of further technologies aimed at reducing embolic complications in structural heart interventions. The dual focus on product launch and research reflects Emboline's strategic planning to address urgent needs in patient care more effectively.

About Trinity Capital Inc.

Serving as a primary resource for innovative enterprises, Trinity Capital Inc. (Nasdaq: TRIN) specializes in providing tailored debt solutions essential for growth-oriented companies. The firm has successfully deployed over $5.5 billion in funding to date across various sectors, including life sciences, reflecting its commitment to supporting burgeoning businesses as they navigate capital requirements.

About Emboline

Founded and operated in Santa Cruz, California, Emboline, Inc. is driven by a vision to revolutionize patient safety within the cardiovascular landscape. The Emboliner® Embolic Protection System, currently in investigational stages, promises a significant leap forward in safeguarding patient health during transcatheter medical procedures. For further information on Emboline and its products, you can visit their official website at emboline.com.

In summary, Emboline's acquisition of substantial funding marks a hopeful milestone for cardiac health innovation that can save lives and instill trust in medical practices.